Skip to main content
EMYRIA LIMITED logo

EMYRIA LIMITED — Investor Relations & Filings

Ticker · EMD ISIN · AU0000073645 LEI · 529900IMZL1QU98KGH07 ASX Professional, scientific and technical activities
Open in API
Filings indexed 440 across all filing types
Latest filing 2023-09-20 Capital/Financing Update
Country AU Australia
Listing ASX EMD

About EMYRIA LIMITED

https://emyria.com

Emyria Limited is a clinical-stage biotechnology company focused on developing and delivering new treatments for mental health and neurological conditions. The company integrates clinical service delivery with data-driven drug development to accelerate the path to market for novel therapies. Emyria operates a network of specialist clinics that provide evidence-based care while collecting high-quality real-world data to inform its drug discovery pipeline. Key focus areas include MDMA-assisted therapy for post-traumatic stress disorder (PTSD) and the development of proprietary cannabinoid-based medicines. Through its partnership with clinical research organizations and mental health specialists, the company aims to provide scalable, data-backed solutions for complex health challenges. Its proprietary data platform supports the identification of new drug targets and the optimization of clinical trial designs.

Recent filings

Filing Released Lang Actions
Emyria Secures Local MDMA to Start PTSD Trial Dosing 4 pages 791.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 21 September 2023 from Emyria Limited. It discusses the securing of MDMA supply for a clinical trial on MDMA-assisted therapy for PTSD, referencing recent clinical trial results, regulatory approvals, and collaborations. The content focuses on operational updates, clinical trial progress, partnerships, and future milestones rather than presenting financial data or detailed financial performance. The document is approximately 13,307 characters, which is substantial but reads as a corporate announcement about clinical and operational progress rather than a financial report or earnings release. There is no indication of financial statements, audit information, or detailed management discussion of financial results. It is not a call transcript, AGM material, or a regulatory filing of a financial nature. The document is best classified as a Capital/Financing Update (CAP) because it relates to securing supply and operational readiness for a clinical trial, which is a material business development and capital-related update for the company. The document is not a report publication announcement or a regulatory filing as it contains substantive information rather than just a notice of report availability. Therefore, the most appropriate classification is CAP with high confidence.
2023-09-20 English
Prospectus & Application Forms Available to Eligible Holders 1
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 18 September 2023 regarding the availability of a Prospectus and Application Forms for a non-renounceable entitlement offer. It discusses the opening and closing dates of the entitlement offer and provides contact information for enquiries. There is no financial data, no detailed report, and no mention of a full financial report or results. The document is an announcement about a capital raising activity (entitlement offer), which fits the category of Capital/Financing Update (CAP). The document length is short (1223 characters), and it is not a report publication announcement or a certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-09-17 English
Application for quotation of securities - EMD 8 pages 30.5KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Application for quotation of +securities' and details the application for quotation of securities issued by Emyria Limited. It references previous announcements, specifically an Appendix 3B, which is a form used in Australian securities markets for new issues of securities. The document includes details about the number and type of securities to be quoted, issue dates, and distribution schedules. There is no financial performance data, earnings information, or management discussion. The document is an official announcement related to the quotation of securities on the ASX, which aligns with announcements about share issues or capital changes. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length is 6605 characters, which is sufficient to contain substantive information about the share issue rather than just a brief announcement of a report publication.
2023-09-12 English
Application for quotation of securities - EMD 9 pages 33.3KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Application for quotation of +securities' and details the issuance and quotation of new securities for Emyria Limited. It includes specifics about the number and type of securities, issue dates, distribution schedules, and references to previous announcements such as Appendix 3B filings. The content focuses on the application to list or quote securities on the ASX, which is a capital market activity related to share issuance and listing. There is no financial performance data, management discussion, or audit information. The document is not a report but an announcement related to capital structure changes and securities quotation. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (8334 characters) and detailed issuance information support this classification with high confidence.
2023-09-12 English
Emyria Completes Acquisition of the Pax Centre 3 pages 782.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 13 Sep 2023 regarding the completion of an acquisition by Emyria Limited. It details the acquisition of the Pax Centre, strategic benefits, clinical delivery milestones, and company background. The content focuses on a corporate transaction (acquisition) and strategic growth rather than financial results, regulatory certifications, or detailed financial statements. It is not a full annual or interim report, nor an earnings release or management discussion. The document is a formal announcement of a corporate acquisition event, which fits the category of Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes through acquisition. The document length (9198 characters) and detailed content confirm it is the announcement itself, not a brief notice or report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2023-09-12 English
Section 708A(5)(e) Notice 1 page 91.4KB
Capital/Financing Update Classification · 95% confidence The document is a Cleansing Notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth), notifying the issuance of new shares and the legal basis for their immediate tradability. It details the number of shares issued, issue price, and references compliance with relevant sections of the Corporations Act. There is no financial report, earnings data, or management discussion. The document is an announcement related to capital raising and share issuance, specifically notifying the market of new shares issued under a placement and acquisition consideration. This fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Therefore, the correct classification is CAP with high confidence.
2023-09-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.